» Articles » PMID: 7589152

CD4/major Histocompatibility Complex Class II Interaction Analyzed with CD4- and Lymphocyte Activation Gene-3 (LAG-3)-Ig Fusion Proteins

Overview
Journal Eur J Immunol
Date 1995 Sep 1
PMID 7589152
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed CD4 major histocompatibility complex (MHC) class II interactions with CD4 and lymphocyte activation gene (LAG)-3 recombinant fusion proteins termed CD4Ig and LAG-3Ig. CD4Ig bound MHC class II molecules expressed on the cell surface only when used in the micromolar range. This weak CD4Ig binding was specific, since it was inhibited by anti-CD4 and anti-MHC class II mAb. LAG-3Ig bound MHC class II molecules with intermediate avidity (Kd = 60 nM at 37 degrees C). Using LAG-3Ig as a competitor in a CD4/MHC class II-dependent cellular adhesion assay, we showed that this recombinant molecule was able to block CD4/MHC class II interaction. In contrast, no inhibition was observed in a CD4/MHC class II-dependent T cell cytotoxicity assay. Together, these results suggest that co-engagement of the TcR with CD4 alters the CD4/MHC class II molecular interaction to become insensitive to LAG-3Ig competition.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.


The Role of YY1 in the Regulation of LAG-3 Expression in CD8 T Cells and Immune Evasion in Cancer: Therapeutic Implications.

Merenstein A, Obeidat L, Zaravinos A, Bonavida B Cancers (Basel). 2025; 17(1.

PMID: 39796650 PMC: 11718991. DOI: 10.3390/cancers17010019.


Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact.

Bertuzzi C, Righi S, Motta G, Rossi M, Carella M, Gabrielli G Cancers (Basel). 2025; 16(24).

PMID: 39766109 PMC: 11674618. DOI: 10.3390/cancers16244210.


Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.

Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.

PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.


Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.

Ren K, Hamdy H, Meyiah A, Elkord E Front Immunol. 2024; 15():1501613.

PMID: 39660130 PMC: 11628531. DOI: 10.3389/fimmu.2024.1501613.